Plasma miR-379 can predict treatment response to FOLFIRINOX and gemcitabine- nab-paclitaxel in advanced pancreatic cancer [0.03%]
血浆miR-379可以预测晚期胰腺癌对FOLFIRINOX和吉西他滨-nab-紫杉醇的治疗反应
Lenka N C Boyd,Mahsoem Ali,Jisce R Puik et al.
Lenka N C Boyd et al.
Background: Novel biomarkers, such as plasma microRNAs (miRs), are needed to help guide clinical decision-making for the type of chemotherapy to use in patients with advanced pancreatic ductal adenocarcinoma (PDAC). This ...
Exploring the clinical utility of liquid biopsy with cfDNA in cancer: A systematic review [0.03%]
探究癌症中cfDNA的液体活检的临床效用：系统性回顾
Keerthi Ranganathan,Neethu Sheri Kurian,Hitesh M Goswami et al.
Keerthi Ranganathan et al.
Various tumor cells may exhibit different genetic or phenotypic characteristics. This phenomenon of cancer cells, known as Tumor Heterogeneity, is responsible for multiple cancer sites caused in a single patient through metastases. It is po...
New perspectives on inoperable early-stage lung cancer management: Clinicians, physicists, and biologists unveil strategies and insights [0.03%]
早期肺癌不可手术治疗的新视角：临床医生、物理学家和生物学家揭示策略与见解
Mauro Buono,Gianluca Russo,Valerio Nardone et al.
Mauro Buono et al.
This work provides a comprehensive overview of the current landscape of lung cancer, emphasizing the global significance of the disease and the challenges associated with its diagnosis and treatment. The authors highlight the prevalence of ...
Multiplex detection of ten ESR1 mutations and AKT1 E17K in breast cancer using digital PCR [0.03%]
使用数字PCR在乳腺癌中检测十个ESR1突变和AKT1 E17K的方法
Stavroula Smilkou,Aliki Ntzifa,Dimitra Stergiopoulou et al.
Stavroula Smilkou et al.
Introduction: ESR1 mutations are now established as a key mechanism of resistance to endocrine therapy in estrogen-receptor-positive breast cancer (ER+ breast cancer) and their sensitive and specific detection in plas...
The role of liquid biopsy as a catalyst for sustained progress in precision oncology - Perspective of the young committee of the international society of liquid biopsy [0.03%]
液体活检在精准肿瘤学持续进展中的催化剂作用-国际液体活检学会青年委员会的观点
Erick F Saldanha,Eleonora Nicolo,Konstantinos Venetis et al.
Erick F Saldanha et al.
Global research trends in liquid biopsy for ovarian cancer from 1999 to 2023: A 25-year bibliometric analysis [0.03%]
1999年至2023年卵巢癌液态活检的全球研究趋势：25年的文献计量分析
Jixian Wan,Zechuan Rao,Huaichao Liu et al.
Jixian Wan et al.
Background: Ovarian cancer (OC) is a major cause of gynecological cancer-related death in the world. Liquid biopsy has shown great potential in improving the ovarian cancer detection and treatment. The aim of this study i...
Erratum [0.03%]
Erratum(erratum的复数)
[This corrects the article DOI: 10.1016/j.jlb.2023.100002.][This corrects the article DOI: 10.1016/j.jlb.2023.100006.][This corrects the article DOI: 10.1016/j.jlb.2023.100118.][This corrects the article DOI: 10.1016/j.jlb.2023.100005.][Thi...
Published Erratum
The journal of liquid biopsy. 2024 Apr 30:5:100155. DOI:10.1016/j.jlb.2024.100155 2024
Early monitoring of plasma KRAS G12C with digital PCR predicts antitumor response to immunotherapy or sotorasib in advanced NSCLC: A brief report [0.03%]
早期利用数字PCR监测晚期非小细胞肺癌血浆KRAS G12C以预测免疫治疗或sotorasib的抗肿瘤反应：简短报告
Andrea De Giglio,Federico Zacchini,Giulia Venturi et al.
Andrea De Giglio et al.
Background: The frontline management of non-oncogene addicted non-small cell lung cancer (NSCLC) involves immune-checkpoint inhibitors (ICI) alone or combined with chemotherapy (CT-ICI). The dynamic landscape of KRAS-posi...
Clinical utility of liquid biopsy in bladder cancer: The beginning of a new era [0.03%]
膀胱癌液检的临床效用：一个新时代的开始
Eric Jia,Gautum Agarwal
Eric Jia
Bladder cancer (BC) is the sixth most prevalent cancer in the U.S. and the most expensive to treat. Integrating precision medicine into BC management promises improved outcomes and reduced costs. This review explores current treatment parad...
Expanding the clinical utility of liquid biopsy by using liquid transcriptome and artificial intelligence [0.03%]
通过使用液体转录组学和人工智能来扩展液体活检的临床应用范围
Maher Albitar,Ahmad Charifa,Sally Agersborg et al.
Maher Albitar et al.
Most of the current utilization of liquid biopsy (LBx) is based on analyzing cell-free DNA(cfDNA). There is limited data on using cell-free RNA (cfRNA) levels (liquid transcriptome) in LBx. The major hurdles for using liquid transcriptome i...